How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Anti-Retroviral Drugs Market
- By Drug Class: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Strand Transfer Inhibitors (INSTIs), Entry Inhibitors
- By Formulation: Oral Tablets, Oral Capsules, Oral Suspensions, Injectable Formulations
- By Therapy Type: First-line Therapy, Second-line Therapy, Salvage Therapy
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government Health Programs
- By Patient Type: Adult Patients, Pediatric Patients
Top segment
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) XX% share · $X,XXXM
In the full report →
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Nucleoside Reverse Transcriptase Inhibitors (NRTIs) leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Anti-Retroviral Drugs Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Formulation 4
Therapy Type 3
Distribution Channel 4
Patient Type 2
Companies profiled
Gilead Sciences
ViiV Healthcare
Johnson & Johnson
Merck & Co.
GlaxoSmithKline
Bristol-Myers Squibb
AbbVie
Mylan (now part of Viatris)
Cipla
Teva Pharmaceutical Industries
F. Hoffmann-La Roche
Aurobindo Pharma
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →ViiV Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merck & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GlaxoSmithKline
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bristol-Myers Squibb
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AbbVie
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mylan (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cipla
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Teva Pharmaceutical Industries
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →F. Hoffmann-La Roche
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Aurobindo Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sun Pharmaceutical Industries
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Emcure Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Hetero Drugs
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$10,625M by 2033 · 8.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)52.2
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)13.1
- Protease Inhibitors (PIs)15.6
- Integrase Strand Transfer Inhibitors (INSTIs)12.2
- Entry Inhibitors6.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,841M → $3,242M · 7.3%
Europe$1,283M → $2,604M · 9.3%
Asia Pacific$1,171M → $2,424M · 9.5%
Latin America$725.1M → $1,479M · 9.3%
Middle East and Africa$557.8M → $1,105M · 8.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.342026
8.362027
8.372028
8.392029
8.392030
8.402031
8.422032
8.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Gilead Sciences18.0
- ViiV Healthcare18.8
- Johnson & Johnson6.6
- Merck & Co.4.0
- GlaxoSmithKline11.2
- Bristol-Myers Squibb13.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class20.4%
Formulation15.0%
Therapy Type26.3%
Distribution Channel17.8%
Patient Type20.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.9
- Europe24.0
- Asia Pacific22.3
- Latin America13.6
- Middle East and Africa10.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Gilead Sciences | 85 | 97 | 75 | 96 | 77 | 87 | 86 |
| ViiV Healthcare | 82 | 90 | 86 | 85 | 89 | 87 | 87 |
| Johnson & Johnson | 85 | 62 | 74 | 71 | 77 | 68 | 73 |
| Merck & Co. | 68 | 82 | 71 | 75 | 57 | 81 | 72 |
| GlaxoSmithKline | 59 | 73 | 52 | 54 | 59 | 52 | 58 |
| Bristol-Myers Squibb | 61 | 66 | 50 | 54 | 56 | 67 | 59 |
| AbbVie | 61 | 64 | 45 | 45 | 51 | 48 | 52 |
| Mylan (now part of Viatris) | 46 | 43 | 57 | 38 | 38 | 59 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Gilead Sciences
- ViiV Healthcare
- Johnson & Johnson
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Gilead Sciences | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| ViiV Healthcare | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Johnson & Johnson | ✓ | − | ✓ | ◐ | ◐ | ◐ |
| Merck & Co. | ◐ | ◐ | ◐ | ✓ | − | ◐ |
| GlaxoSmithKline | − | ◐ | − | ◐ | ◐ | − |
| Bristol-Myers Squibb | ◐ | − | − | ◐ | − | ✓ |
| AbbVie | − | ✓ | − | ◐ | ◐ | − |
| Mylan (now part of Viatris) | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1ViiV Healthcare87
2Gilead Sciences86
3Johnson & Johnson73
4Merck & Co.72
5Bristol-Myers Squibb59
6GlaxoSmithKline58
7AbbVie52
8Mylan (now part of Viatris)47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Gilead SciencesViiV Healthcare
Challenger2
Strong scale, closing on the leaders.
Johnson & JohnsonMerck & Co.
Contender2
Focused players with pockets of strength.
GlaxoSmithKlineBristol-Myers Squibb
Niche2
Specialists in a single segment or region.
AbbVieMylan (now part of Viatris)
Go-to-market strategy
Land Drug Class in North America, then scale across Anti-Retroviral Drugs Market — a $232M beachhead inside a $3.59B market.
Beachhead (SOM)$232Mobtainable near-term
Serviceable (SAM)$1.29Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Best fit — highest urgency & budget in Drug Class.
Economic buyer78 fit
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Strong fit — clear ROI and a fast path to value.
End user67 fit
Protease Inhibitors (PIs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Formulation & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapy Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Anti-Retroviral Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation13%
Closed-won6%
$13.7KCAC
$56KLTV
4.1:1LTV : CAC
< 4 moCAC payback
Investment thesis
Anti-Retroviral Drugs Market is a high-growth opportunity — $10.6B by 2033, compounding at 11.5%.
TAM · 2025$4.45Btoday
TAM · 2033$10.6Bforecast
CAGR11.5%2027–2033
Cumulative$64.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.6BTotal addressable market
SAM$3.67BServiceable available market
SOM$662MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.5% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.6BLarge & growingTAM by 2033 at 11.5% CAGR
$3.67BServiceable nowreachable with today’s model
$662MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.27BBear7.4% CAGR
$10.6BBase11.5% CAGR
$13.6BBull15.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Formulation optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Anti-Retroviral Drugs Market — a $2.56B market by 2033. Plan: grow share from 7.9% to 14.9%.
Market size · 2033$2.56Btotal addressable
Market CAGR4.8%2027–2033
Target share14.9%from 7.9% today
Revenue ambition$382Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 14.9% | At risk |
| Revenue | $199M | $382M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.3% | 39.9% | At risk |
| Customer retention | 90.7% | 96.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Formulation capability
A defensible second engine — invest in Formulation to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Formulation
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $40M capacity & capability investment
- Greenlight bolt-on M&A in Formulation
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentBehind
Sales deck · value proposition
Win the Anti-Retroviral Drugs Market conversation — a $3.10B market you can size, segment and defend in minutes.
Market size · 2033$3.10Btotal opportunity
Growth5.3%CAGR to 2033
Addressable buyers1,264+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 4 mopayback period
$52K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Gilead SciencesViiV HealthcareJohnson & JohnsonMerck & Co.GlaxoSmithKlineBristol-Myers SquibbAbbVieMylan (now part of Viatris)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Anti-Retroviral Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Anti-Retroviral Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Bone Morphogenetic Proteins Market
Market size, share, segmentation and regional forecast.
$12.5B by 2032 · 5.03% CAGR
View reportCellulite Treatment Market
Market size, share, segmentation and regional forecast.
$7.6B by 2033 · 10.27% CAGR
View reportOral Anti-Diabetic Drug Market
Market size, share, segmentation and regional forecast.
$10.1B by 2031 · 10.30% CAGR
View reportCutaneous Fribrosis Treatment Market
Market size, share, segmentation and regional forecast.
$9.5B by 2031 · 6.87% CAGR
View reportSaline Laxatives Market
Market size, share, segmentation and regional forecast.
$2.0B by 2032 · 7.36% CAGR
View reportNebulizers Market
Market size, share, segmentation and regional forecast.
$3.9B by 2032 · 7.40% CAGR
View reportOxytocic Pharmaceuticals Market
Market size, share, segmentation and regional forecast.
$9.3B by 2032 · 9.95% CAGR
View reportHypertension Drugs Market
Market size, share, segmentation and regional forecast.
$3.3B by 2031 · 9.88% CAGR
View reportHepatitis C Drugs Market
Market size, share, segmentation and regional forecast.
$12.5B by 2031 · 3.61% CAGR
View reportHepatocellular Carcinoma Drugs Market
Market size, share, segmentation and regional forecast.
$5.0B by 2031 · 5.64% CAGR
View reportChemotherapy Induced Nausea and Vomiting (CINV) Drugs Market
Market size, share, segmentation and regional forecast.
$13.2B by 2033 · 8.64% CAGR
View reportBioengineered Proteins Drugs Market
Market size, share, segmentation and regional forecast.
$4.7B by 2032 · 9.02% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.